CN119654165A - 使用pi3激酶抑制剂与检查点抑制剂的组合来筛查和治疗多形性胶质母细胞瘤和其他癌症(包括乳腺癌)的方法和产品 - Google Patents
使用pi3激酶抑制剂与检查点抑制剂的组合来筛查和治疗多形性胶质母细胞瘤和其他癌症(包括乳腺癌)的方法和产品 Download PDFInfo
- Publication number
- CN119654165A CN119654165A CN202380044911.1A CN202380044911A CN119654165A CN 119654165 A CN119654165 A CN 119654165A CN 202380044911 A CN202380044911 A CN 202380044911A CN 119654165 A CN119654165 A CN 119654165A
- Authority
- CN
- China
- Prior art keywords
- cells
- cancer
- combination
- treatment
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329096P | 2022-04-08 | 2022-04-08 | |
| US63/329,096 | 2022-04-08 | ||
| US202263368499P | 2022-07-15 | 2022-07-15 | |
| US63/368,499 | 2022-07-15 | ||
| PCT/US2023/065433 WO2023196899A2 (en) | 2022-04-08 | 2023-04-06 | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119654165A true CN119654165A (zh) | 2025-03-18 |
Family
ID=88243701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380044911.1A Pending CN119654165A (zh) | 2022-04-08 | 2023-04-06 | 使用pi3激酶抑制剂与检查点抑制剂的组合来筛查和治疗多形性胶质母细胞瘤和其他癌症(包括乳腺癌)的方法和产品 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250228863A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504264A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511969A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250044594A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119654165A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023249640A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255739A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012457A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196899A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| RU2016148441A (ru) * | 2014-05-21 | 2018-06-22 | Ф. Хоффманн-Ля Рош Аг | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом |
| US20190038713A1 (en) * | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2020215037A1 (en) * | 2019-04-18 | 2020-10-22 | The Regents Of The University Of Michigan | Combination with checkpoint inhibitors to treat cancer |
| PH12023550160A1 (en) * | 2020-07-31 | 2023-09-18 | Exelixis Inc | Combinations for the Treatment of Cancer |
-
2023
- 2023-04-06 US US18/854,796 patent/US20250228863A1/en active Pending
- 2023-04-06 CA CA3255739A patent/CA3255739A1/en active Pending
- 2023-04-06 CN CN202380044911.1A patent/CN119654165A/zh active Pending
- 2023-04-06 JP JP2024559691A patent/JP2025511969A/ja active Pending
- 2023-04-06 EP EP23785623.2A patent/EP4504264A4/en active Pending
- 2023-04-06 AU AU2023249640A patent/AU2023249640A1/en active Pending
- 2023-04-06 WO PCT/US2023/065433 patent/WO2023196899A2/en not_active Ceased
- 2023-04-06 KR KR1020247036529A patent/KR20250044594A/ko active Pending
-
2024
- 2024-10-07 MX MX2024012457A patent/MX2024012457A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012457A (es) | 2025-03-07 |
| KR20250044594A (ko) | 2025-04-01 |
| CA3255739A1 (en) | 2023-10-12 |
| WO2023196899A2 (en) | 2023-10-12 |
| JP2025511969A (ja) | 2025-04-16 |
| WO2023196899A9 (en) | 2023-12-21 |
| AU2023249640A1 (en) | 2024-10-24 |
| US20250228863A1 (en) | 2025-07-17 |
| EP4504264A4 (en) | 2026-03-11 |
| WO2023196899A3 (en) | 2023-11-23 |
| EP4504264A2 (en) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Du et al. | Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy | |
| Folkerts et al. | The multifaceted role of autophagy in cancer and the microenvironment | |
| Yang et al. | The role of autophagy in cancer: therapeutic implications | |
| Nooshabadi et al. | Impact of atorvastatin loaded exosome as an anti-glioblastoma carrier to induce apoptosis of U87 cancer cells in 3D culture model | |
| Pan et al. | Near‐infrared laser‐activated aggregation‐induced emission nanoparticles boost tumor carbonyl stress and immunotherapy of breast cancer | |
| Inoue et al. | CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth | |
| KR20230059792A (ko) | 암 치료를 위한 조합 | |
| JP2020183445A (ja) | 医薬組成物 | |
| US9649313B2 (en) | Use of ITK inhibitors for the treatment of cancer | |
| JP2021001237A (ja) | がん処置のための組み合わせ療法 | |
| US20250228863A1 (en) | Methods and Products to Screen and Treat Glioblastoma Multiforme and Other Cancers, Including Breast Cancers, Using A Combination of PI3KINASE Inhibitors With Checkpoint Inhibitors | |
| US20250339549A1 (en) | Methods for the detection and treatment of non-small-cell lung cancer | |
| WO2022192372A1 (en) | Methods and compositions for tusc2 combination therapy with pdk1 inhibition | |
| Shia et al. | Preclinical pharmacokinetic, pharmacodynamic, and safety profile of OBI-992: a novel TROP2-targeted antibody–drug conjugate | |
| EP2061464A2 (en) | Combination therapy for tumoral disease treatment | |
| US20100256136A1 (en) | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | |
| JP2016502974A (ja) | Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 | |
| CN115414363B (zh) | 抗肝癌组合物和苯乙双胍在制备抗肝癌药物增敏剂的应用 | |
| US20250099426A1 (en) | Indolium Compounds for Treating Cancer | |
| Alexiou et al. | Systemic chemotherapy in brain gliomas | |
| JP6993812B2 (ja) | 細胞傷害活性を向上させたリンパ球の培養方法及び該方法で得られた細胞傷害活性を向上させたリンパ球を含む細胞免疫治療剤 | |
| US20220257777A1 (en) | Hsp90-binding conjugates and combination therapies thereof | |
| EP4288444A1 (en) | Rationale, design, synthesis and validation of a small molecule anticancer agent | |
| Abrahamse et al. | Cancer stem cells | |
| Davis | Identification of novel heat shock response modulators for experimental anti-melanoma intervention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |